Form 8-K - Current report:
SEC Accession No. 0001193125-26-073456
Filing Date
2026-02-26
Accepted
2026-02-26 07:45:25
Documents
12
Period of Report
2026-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-20260226.htm   iXBRL 8-K 48107
2 EX-99.1 ntla-ex99_1.htm EX-99.1 169991
3 GRAPHIC img149557450_0.jpg GRAPHIC 36750
  Complete submission text file 0001193125-26-073456.txt   388501

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20260226.xsd EX-101.SCH 25023
14 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20260226_htm.xml XML 4763
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 26681740
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)